Many startup companies developing psychedelic medicines are struggling to raise money these days. Not Gilgamesh Pharmaceuticals. Founded in 2019, Gilgamesh raised $39m in December. Its original investors came back for the Series B round. It participated in the Y Combinator accelerator for startups. Its founder, Jonathan Sporn, who I met briefly at a party during …
Nonprofit Chronicles 